Older age linked to depression risk in glaucoma patients

Article

Older glaucoma patients are more at risk of developing depression, whereas younger patients are more at risk of anxiety

Older glaucoma patients are more at risk of developing depression, whereas younger patients are more at risk of anxiety, according to a paper in the British Journal of Ophthalmology.

The stepwise linear regression analysis, led by Dr Fumihiko Mabuchi, Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Japan, included 208 glaucomatous patients. Each participant was evaluated using the hospital anxiety and depression (HADS) questionnaire split into two subscales- the HADS-anxiety (HADS-A) and HADS-depression (HADS-D).

For both HADS-A and HADS-D the regression analysis revealed that age was a significant related factor. The correlation between age and HADS-A was proven by the results of the multiple linear regression analysis.

Overall, younger glaucoma patients were more likely to suffer from anxiety, whereas older glaucoma patients were more at risk of depression.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.